Cytek Bioscience News Today

FREMONT, Calif., Feb. 28, 2024 -- Cytek® Biosciences, Inc. , a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2023....

Key Insights Given the large stake in the stock by institutions, Cytek Biosciences' stock price might be vulnerable to...

FREMONT, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell anal...

FREMONT, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2023.

SALUGGIA, Italy, and FREMONT, Calif., Feb. 28, 2023 -- DiaSorin and Cytek Biosciences, Inc. today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has completed the... | February 28, 2023

10.08.2022 - Second quarter revenue grew 32% compared to prior yearFREMONT, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) - Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, ...

Cytek Biosciences (NASDAQ:CTKB – Get Rating) is one of 43 public companies in the “Analytical instruments” industry, but how does it weigh in compared to its peers? We will compare Cytek Biosciences to similar businesses based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, risk, profitability and dividends. Analyst Ratings This is […]

Cytek Biosciences (NASDAQ:CTKB – Get Rating) and Bio-Rad Laboratories (NYSE:BIO.B – Get Rating) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation. Analyst Ratings This is a summary of recent ratings for […]

Cytek Biosciences (NASDAQ:CTKB – Get Rating) is one of 42 publicly-traded companies in the “Analytical instruments” industry, but how does it contrast to its competitors? We will compare Cytek Biosciences to related businesses based on the strength of its valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and earnings. Institutional & Insider Ownership 36.0% of […]

Cytek Biosciences (NASDAQ:CTKB – Get Rating) is one of 42 publicly-traded companies in the “Analytical instruments” industry, but how does it weigh in compared to its peers? We will compare Cytek Biosciences to related businesses based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, earnings, risk and valuation. Profitability This table compares […]